Connect with us

Public Companies

Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, today announced it has been selected…

Published

on

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults.1 The phase II randomized clinical study for the acute treatment of SAD (the “PREVAIL Trial”) is sponsored by Bionomics Limited, a clinical-stage biopharmaceutical company (“Bionomics”) (Nasdaq: BNOX | ASX: BNO) and is currently enrolling patients at Novamind’s Draper, Utah, research site.

The PREVAIL Trial will examine the safety and efficacy of Bionomics’ propriety drug candidate, BNC210, versus a placebo in reducing self-reported anxiety severity when participants take part in an anxiety-provoking behavioral task involving a speaking challenge. People with SAD experience extreme fear in social situations, when meeting new people or speaking in front of others, which can severely and negatively impact relationships, work and daily life. Current medical interventions include SSRIs, beta-blockers and anti-anxiety medications such as benzodiazepines.

“Social Anxiety Disorder is an understudied mental health condition and yet it’s very common with widespread impact across multiple domains of life. Existing medications for social anxiety are slow to work or are fraught with adverse effects. It’s exciting to participate in studying a drug with a novel mechanism like BNC210 that could offer patients an alternate treatment option.”

Dr. Reid Robison, Chief Medical Officer and Principal Investigator

The PREVAIL Trial is the second Bionomics study hosted by Novamind. In 2021, the Company announced it was selected to host a phase IIb randomized clinical trial investigating BNC210 as a treatment for PTSD. BNC210 has Fast Track designations from the U.S. Food and Drug Administration for the treatment of both PTSD and SAD, a process designed to facilitate development and expedite the review of drugs that address an unmet medical need for serious conditions.

Dr. Robison continued, “Working with leading drug developers continues to advance critical mental health research through a variety of compounds and widens the spectrum of conditions under investigation at Novamind’s clinical research sites.”

Novamind is focused on bringing innovative treatments to the world through its clinical research sites and is currently investigating new treatments for PTSD, Tourette’s Syndrome, schizophrenia, treatment-resistant depression, major depressive disorder, traumatic brain injury, bipolar disorder and autism.

To learn more about the PREVAIL Trial, please visit this link.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Read More

Trending